Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.41 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | SGK1 | O00141 | 1/20 | 0.36 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.35 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856092 | 0.89 | CYP3A4 (0.40) | AXLCYP3A4MAP4K1NEK1SGK1 | |
| SCHEMBL8242206 | 0.88 | AXL (0.41) | AXLCYP3A4MAP4K1NEK1NTRK1 | |
| Butyramide SCHEMBL27984563 | 0.86 | AXL (0.41) | AXLCYP3A4MAP4K1NEK1NTRK1 | |
| SCHEMBL856131 | 0.85 | MTNR1A (0.44) | CYP3A4MAP4K1OXER1 | |
| SCHEMBL7951947 | 0.84 | PDPK1 (0.39) | AXLCYP3A4MAP4K1NEK1NTRK1 | |
| SCHEMBL413921 | 0.80 | PDPK1 (0.42) | CYP3A4MAP4K1NEK1NTRK1PDPK1 | |
| Butyramide SCHEMBL28814303 | 0.78 | PDPK1 (0.42) | AXLCYP3A4MAP4K1NEK1NTRK1 | |
| SCHEMBL10261181 | 0.78 | ICMT (0.37) | OXER1 | |
| SCHEMBL858744 | 0.76 | ALK (0.43) | CYP3A4MAP4K1PDPK1PAK4PAK1 | |
| SCHEMBL8249503 | 0.76 | CYP3A4 (0.40) | AXLCYP3A4MAP4K1NEK1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-11-14 | — | — | US | disclosed |
| US-8143271-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-01-26 | — | — | US | disclosed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | AXL 1354/4885CYP3A4 4658/4885MAP4K1 15/4885 |
| US-20130303534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | AXL 1354/4885CYP3A4 4658/4885MAP4K1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.